Cedar Hill Associates’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Cedar Hill Associates’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	$419K	Buy	+5,845	New	+$471K	0.16%	80

Other funds holding XBI

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

BCWM LLC Overland Park, Kansas $353M AUM 20.1% 1-Year Est. Return

Cedar Hill Associates's XBI Position: Q4 2018 in Review

Cedar Hill Associates opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q4 2018: 5,845 shares worth $419K. The stake represents 0.16% of the portfolio and ranks #80 among its holdings.

427 funds tracked by Wall St. Rank hold XBI as of Q4 2018.

Cedar Hill Associates held 5,845 shares of State Street SPDR S&P Biotech ETF worth $419K as of Q4 2018.
State Street SPDR S&P Biotech ETF was a new Cedar Hill Associates position in Q4 2018.
State Street SPDR S&P Biotech ETF made up 0.16% of Cedar Hill Associates's portfolio in Q4 2018, its #80 holding.
427 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2018.

Based on Cedar Hill Associates's 13F filing for Q4 2018, filed 13 Feb 2019.